Home » Stocks » PASG

Passage Bio, Inc. (PASG)

Stock Price: $28.24 USD -1.59 (-5.33%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $28.50 +0.26 (0.92%) Jan 15, 7:05 PM
Market Cap 1.29B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 45.50M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $28.24
Previous Close $29.83
Change ($) -1.59
Change (%) -5.33%
Day's Open 29.91
Day's Range 27.67 - 29.95
Day's Volume 186,499
52-Week Range 8.86 - 36.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice Presid...

Other stocks mentioned: PHAT
GlobeNewsWire - 1 week ago

PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

GlobeNewsWire - 1 week ago

FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study,  expected to dose first patient in first quarter 2021

GlobeNewsWire - 4 weeks ago

- Company invests to build in-house capabilities to support advancement of pipeline -

GlobeNewsWire - 1 month ago

- MHRA approval represents first clinical trial authorization for the global PBGM01 clinical trial program -

GlobeNewsWire - 1 month ago

- Completion of dedicated CGMP suite enhances manufacturing readiness and secures supply chain control to support lead CNS gene therapy product candidates as they advance through clinical tria...

GlobeNewsWire - 1 month ago

PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

GlobeNewsWire - 2 months ago

Through its unique collaboration agreement, Passage Bio has certain rights to technology highlighted in the University's research, which has the potential to significantly advance nascent fiel...

GlobeNewsWire - 2 months ago

PHILADELPHIA, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

Seeking Alpha - 2 months ago

Passage Bio, Inc. (PASG) CEO Karl Bruce Goldsmith on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

– Dosing for first patient in PBGM01 Phase 1/2 trial anticipated in 1Q2021; initial safety and biomarker data expected mid-year 2021 – – Phase 1/2 clinical trials for FTD-GRN and Krabbe expect...

GlobeNewsWire - 2 months ago

Genetic testing, educational materials and counseling offered at no charge to patients Genetic testing, educational materials and counseling offered at no charge to patients

GlobeNewsWire - 2 months ago

PHILADELPHIA, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

GlobeNewsWire - 2 months ago

PHILADELPHIA, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

GlobeNewsWire - 2 months ago

PHILADELPHIA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous...

Zacks Investment Research - 3 months ago

Passage Bio (PASG) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

About PASG

Passage Bio, a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Industry
Biotechnology
IPO Date
Feb 28, 2020
Stock Exchange
NASDAQ
Ticker Symbol
PASG
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Passage Bio stock is "Buy." The 12-month stock price forecast is 29.13, which is an increase of 3.15% from the latest price.

Price Target
$29.13
(3.15% upside)
Analyst Consensus: Buy